Skip to content
  • Select your language
    • English
    • French
    • Spanish
    • Italian
    • German
    • Japanese
    • Simplified Chinese

Language

Login
Register
ES – Journey to a New Era for Alzheimer’s Disease
  • Home
  • About the Program
  • Faculty
  • Ask a Question
Home About the Program Faculty Ask a Question

AD/PD™️ 2024 Lisbon, Portugal – March 5 – 9, 2024

Home > Contenido > AD/PD™️ 2024 Lisbon, Portugal – March 5 – 9, 2024

AD/PD focuses on basic science and translational and clinical research in Alzheimer’s disease and Parkinson’s disease, bringing key advances in disease mechanisms, innovative therapies, and diagnostic biomarkers.

Conference Content

News Nuggets
ADPD 2024 – Noticias en breve – Mejora del aclaramiento de amiloide a los 18 meses con donanemab frente a aducanumab
ADPD 2024 – Noticias en breve – El nivel inicial de amiloide es el principal factor predictivo del aclaramiento de amiloide con el tratamiento con donanemab
ADPD 2024 – Noticias en breve – La investigación destaca la capacidad predictiva de p-tau 217 por sí sola y combinada con p-tau 231
AD/PD™️ 2024 – Noticias en breve – 4 – Los efectos modificadores de la enfermedad de lecanemab en la EA se mantienen durante 24 meses
AD/PD™️ 2024 – Noticias en breve – 5 – La modelización de los datos arroja luz sobre el equilibrio entre la eficacia y la seguridad del donanemab
Breakfast Bytes - Video
AD/PD™️ 2024 – Breakfast Bite – Highlights of latest research on fluid biomarkers
AD/PD™️ 2024 – Breakfast Bite – Highlights research on earlier treatment with anti-amyloid immunotherapies
Breakfast Bytes - Podcast
AD/PD™️ 2024 – Breakfast Bite 1 – Podcast
AD/PD™️ 2024 – Breakfast Bite 2 – Podcast
Content Menu

Click to Provide Flash Feedback

12345678910
1 = poor, 10 = excellent
Strongly disagreeDisagreeNeutralAgreeStrongly agree
Strongly disagreeDisagreeNeutralAgreeStrongly agree
YesNo
This field is for validation purposes and should be left unchanged.

¿Le gusta este contenido?

Únase a este programa para acceder a contenidos acreditados de primera calidad y obtener créditos CME durante todo el año

Inscríbase ahora

Privacy Policy
Terms and Conditions

Contact us: ime@springer.com

This activity is supported by an educational grant from Lilly.

Program start date: 4th March 2024
Program end date: 30th June 2025

This content was last updated on 31st July 2024

Follow Us:

  • LinkedIn
  • Facebook
  • X

Manage cookie preferences

© 2024 Springer Healthcare Ltd | Website by Arttia Creative